ArticleMedical oncology (Northwood, London, England)2025
Selective regulation and cellular metabolism by the lactate transporter MCT4 in GBM.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cancer stem cell plasticity: mechanisms, immune microenvironment crosstalk, and therapeutic implications.Journal of hematology & oncology · 2026Review
- Noninvasive assessment of core metastatic genes in lung adenocarcinoma: development of a predictive model integrating single-cell transcriptomics and radiomics.Frontiers in oncology · 2026Article
- The enzymatic mechanisms of lactylation and its role in gynecological diseases: a comprehensive review.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoxia drives adaptive gene expression in glioblastoma (GBM), influencing tumor progression and metabolic reprogramming. This study investigated the hypoxic response of a patient-derived GBM cancer stem cell line, identifying key hypoxia-inducible genes such as SLC16A3, CA9, BNIP3, VEGFA, and NDRG1. SLC16A3 encodes the lactate transporter MCT4, whose expression has been implicated in biology of several cancers, including GBM. To evaluate role of MCT4, its expression was transiently reduced using siRNA resulting in an attenuated hypoxic induction of NDRG1 and SOX2, while sparing CA9 and BNIP3. Immunoblotting of GBM patient tissues revealed heterogeneous co-expression of MCT4 and NDRG1, highlighting a possible metabolic diversity within tumors. Moreover, metabolomic data of the cells showed dysregulated metabolites such as elevated stearic acid and decreased levels of D-( +)-2-phosphoglyceric acid, lactic acid, purine, pyridoxal, N,N,N-trimethyl lysine, and phosphatidylcholine (18:1/18:1) (del9-trans). Decreased intracellular lactate and increased acidity under hypoxic conditions, confirmed important role of MCT4 role in lactate transport and pH regulation. By establishing central role of MCT4 in hypoxia-driven processes, this study provides valuable insights into GBM metabolic plasticity and suggests that MCT4 might be potential therapeutic target.
Indexed as
Identifiers
41003809What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.